After confirming the in vitro activity of IBC against Aβ clearance and NLRP3 inflammasome, the two important targets in AD, we validated its efficacy in the 5x-FAD transgenic mouse model of the disease. The gene discussed is NLRP3; the disease is Alzheimer disease.